Multicentre study of l-alpha-glyceryl-phosphorylcholine vs ST200 among patients with probable senile dementia of Alzheimer's type
Key Finding
Alpha-GPC (1200mg daily) significantly improved cognition and functioning in Alzheimer's patients over 180 days.
Plain-English Summary
This randomized, double-blind, placebo-controlled study examined alpha-GPC (choline alfoscerate, 1200mg daily) in 261 patients with mild-to-moderate Alzheimer's disease over 180 days. Cognitive and functional outcomes were assessed using validated scales.
Alpha-GPC produced statistically significant improvements in cognitive function (ADAS-Cog scores), behavioural symptoms, and functional abilities compared to placebo. Improvements were observed from day 90 and continued through day 180.
Alpha-GPC is the most bioavailable form of choline for the brain. It directly provides choline for acetylcholine synthesis - the neurotransmitter most affected in Alzheimer's disease. Alpha-GPC also contributes to phosphatidylcholine synthesis, supporting neuronal membrane integrity. The supplement was well-tolerated with few adverse effects compared to pharmaceutical cholinesterase inhibitors.